BioCentury | May 26, 2020
Distillery Therapeutics

Blocking inhibitor of apoptosis proteins in liver cells to treat malaria

DISEASE CATEGORY: Infectious disease INDICATION: Malaria Targeting IAP, a family of apoptosis-blocking proteins that includes BIRC2 and BIRC3, could treat malaria by clearing liver infection. In mice infected with Plasmodium berghei sporozoites, the parasite stage...
BC Week In Review | Nov 3, 2016
Company News

TetraLogic, Medivir deal

Medivir will acquire birinapant and suberohydroxamic acid phenyl ester (SHAPE) from TetraLogic for $12 million up front in cash; TetraLogic will subsequently delist from NASDAQ and terminate all remaining employees by Dec. 1. TetraLogic shareholders...
BioCentury | Apr 4, 2016

None shall pass

Biotech recorded its worst quarter in about 14 years, and no market cap bands were spared from the carnage. Big caps, normally a safe haven during turbulent markets, shed 16.1% and had only three of...
BC Week In Review | Feb 1, 2016
Clinical News

Birinapant: Phase II discontinued

TetraLogic said it will terminate a double-blind, international Phase II trial after an interim analysis of 62 evaluable azacitidine-naive patients with higher risk MDS showed that twice-weekly 13 mg/m 2 IV birinapant for 3 weeks...
BC Week In Review | Jul 27, 2015
Clinical News

Birinapant: Preliminary Phase IIa data

Preliminary data from 9 azacitidine-naive patients with higher risk MDS in a double-blind, placebo-controlled, international Phase IIa trial showed that twice-weekly 13 mg/m 2 IV birinapant for 3 weeks of a 4-week cycle plus azacitidine...
BC Week In Review | May 25, 2015
Clinical News

Birinapant: Phase Ib/IIa halted

TetraLogic temporarily halted enrollment in a double-blind, placebo-controlled, Australian Phase Ib/IIa trial of IV birinapant following observed cranial nerve palsies in 2 of the 7 patients in the first cohort receiving the 1.4 mg/m 2...
BC Week In Review | May 18, 2015
Company News

TetraLogic, Merck deal

TetraLogic and Merck will jointly conduct a Phase I trial evaluating TetraLogic’s birinapant in combination with Merck’s Keytruda pembrolizumab to treat relapsed or refractory solid tumors. TetraLogic will fund the study, and Merck will provide...
BC Week In Review | Jun 30, 2014
Clinical News

Birinapant: Preliminary Phase Ib/IIa data

Preliminary data from 9 evaluable MDS patients in the dose-escalation Phase Ib portion of the open-label, U.S. Phase Ib/IIa TL32711-0087 trial showed that birinapant plus azacitidine led to a bone marrow blast count reduction from...
BC Week In Review | Feb 3, 2014
Company News

TetraLogic, Walter and Eliza Hall Institute of Medical Research deal

The institute and TetraLogic partnered to develop birinapant to treat viral infections. The institute granted TetraLogic an exclusive, worldwide license to a patent application related to a method of treating intracellular infections involving the administration...
BC Extra | Dec 13, 2013
Financial News

TetraLogic raises $50.1 million in IPO

Cancer company TetraLogic Pharmaceuticals Corp. (NASDAQ:TLOG) raised $50.1 million in an IPO through the sale of 7.2 million shares at $7, which values TetraLogic at $147.8 million. On Tuesday, the company had amended the offering...
Items per page:
1 - 10 of 20